
Amlodipine (5mg) + Hydrochlorothiazide (12.5mg) + Olmesartan Medoxomil (20mg)
Active composition
+2 more active ingredients
Amlodipine inhibits calcium ion influx into vascular smooth muscle and cardiac muscle, leading to vasodilation and reduced myocardial oxygen demand.
Hydrochlorothiazide inhibits sodium reabsorption in the distal convoluted tubule, leading to increased urine output and decreased blood volume.
Olmesartan Medoxomil blocks angiotensin II receptors, preventing vasoconstriction and lowering blood pressure.
Medical applications
Olmiwave-20 AMH Tablet is a combination antihypertensive medication containing Olmesartan Medoxomil (20 mg), Amlodipine (5 mg), and Hydrochlorothiazide (12.5 mg). This formulation is indicated for the management of hypertension, providing effective blood pressure control through complementary mechanisms of action. Olmesartan Medoxomil is an angiotensin II receptor blocker (ARB) that inhibits vasoconstriction and aldosterone secretion, thereby reducing peripheral vascular resistance. Amlodipine, a calcium channel blocker, promotes vasodilation by inhibiting calcium ion influx into vascular smooth muscle and cardiac muscle, further aiding in blood pressure reduction. Hydrochlorothiazide is a thiazide diuretic that facilitates sodium and water excretion, decreasing plasma volume and cardiac output. The combination of these agents offers synergistic antihypertensive effects, improving efficacy while potentially minimizing adverse effects associated with higher doses of individual drugs. Olmiwave-20 AMH is suitable for patients who require multiple drug therapy to achieve target blood pressure levels. It is essential to monitor renal function, electrolyte balance, and blood pressure regularly during treatment. Contraindications include hypersensitivity to any component, anuria, and severe renal or hepatic impairment. Use with caution in patients with electrolyte imbalances or gout.
Dosage information not available. Please consult your doctor or pharmacist.
Important precautions
Based on clinical trials and patient reports.
Overall Tolerance
Common Side Effects
Olmiwave-20 AMH Tablet is unsafe to use during pregnancy as there is definite evidence of risk to the developing baby. However, the doctor may rarely prescribe it in some life-threatening situations if the benefits are more than the potential risks. Please consult your doctor.
High Risk
Olmiwave-20 AMH Tablet is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.
Medical Advice
Olmiwave-20 AMH Tablet should be used with caution in patients with severe kidney disease. Dose adjustment of Olmiwave-20 AMH Tablet may be needed. Please consult your doctor. Use of Olmiwave-20 AMH Tablet is not recommended in patients with severe kidney disease.
Exercise Caution
Olmiwave-20 AMH Tablet may cause side effects which could affect your ability to drive. Olmiwave-20 AMH Tablet may cause side effects such as dizziness, headaches, nausea or tiredness, all of which could affect your ability to concentrate and drive.
Consult Doctor
Olmiwave-20 AMH Tablet should be used with caution in patients with liver disease. Dose adjustment of Olmiwave-20 AMH Tablet may be needed. Please consult your doctor.
Regular Checkup
0 reviews for Olmiwave-20 AMH Tablet

Olmesartan Medoxomil (20mg) + Amlodipine (5mg) + Hydrochlorothiazide (12.5mg)
Cheaper alternative availability
This medicine doesn't have a cheaper alternative with the same composition. Our health advisors can help you find other savings options based on your prescription.
Active composition
+2 more active ingredients
Amlodipine inhibits calcium ion influx into vascular smooth muscle and cardiac muscle, leading to vasodilation and reduced myocardial oxygen demand.
Hydrochlorothiazide inhibits sodium reabsorption in the distal convoluted tubule, leading to increased urine output and decreased blood volume.
Olmesartan Medoxomil blocks angiotensin II receptors, preventing vasoconstriction and lowering blood pressure.
Medical applications
Olmiwave-20 AMH Tablet is a combination antihypertensive medication containing Olmesartan Medoxomil (20 mg), Amlodipine (5 mg), and Hydrochlorothiazide (12.5 mg). This formulation is indicated for the management of hypertension, providing effective blood pressure control through complementary mechanisms of action. Olmesartan Medoxomil is an angiotensin II receptor blocker (ARB) that inhibits vasoconstriction and aldosterone secretion, thereby reducing peripheral vascular resistance. Amlodipine, a calcium channel blocker, promotes vasodilation by inhibiting calcium ion influx into vascular smooth muscle and cardiac muscle, further aiding in blood pressure reduction. Hydrochlorothiazide is a thiazide diuretic that facilitates sodium and water excretion, decreasing plasma volume and cardiac output. The combination of these agents offers synergistic antihypertensive effects, improving efficacy while potentially minimizing adverse effects associated with higher doses of individual drugs. Olmiwave-20 AMH is suitable for patients who require multiple drug therapy to achieve target blood pressure levels. It is essential to monitor renal function, electrolyte balance, and blood pressure regularly during treatment. Contraindications include hypersensitivity to any component, anuria, and severe renal or hepatic impairment. Use with caution in patients with electrolyte imbalances or gout.
Dosage information not available. Please consult your doctor or pharmacist.
Important precautions
Based on clinical trials and patient reports.
Overall Tolerance
Common Side Effects
Olmiwave-20 AMH Tablet is unsafe to use during pregnancy as there is definite evidence of risk to the developing baby. However, the doctor may rarely prescribe it in some life-threatening situations if the benefits are more than the potential risks. Please consult your doctor.
High Risk
Olmiwave-20 AMH Tablet is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.
Medical Advice
Olmiwave-20 AMH Tablet should be used with caution in patients with severe kidney disease. Dose adjustment of Olmiwave-20 AMH Tablet may be needed. Please consult your doctor. Use of Olmiwave-20 AMH Tablet is not recommended in patients with severe kidney disease.
Exercise Caution
Olmiwave-20 AMH Tablet may cause side effects which could affect your ability to drive. Olmiwave-20 AMH Tablet may cause side effects such as dizziness, headaches, nausea or tiredness, all of which could affect your ability to concentrate and drive.
Consult Doctor
Olmiwave-20 AMH Tablet should be used with caution in patients with liver disease. Dose adjustment of Olmiwave-20 AMH Tablet may be needed. Please consult your doctor.
Regular Checkup
0 reviews for Olmiwave-20 AMH Tablet















